Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Janssen Biotech gets global rights to Astellas Pharma's ASP015K; terminated

Executive Summary

Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global rights to Astellas Pharma Inc.’s ASP015K, an oral small-molecule JAK1 inhibitor for immune-mediated inflammatory diseases. The deal excludes Japan, where Astellas will continue to develop the compound independently.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies